Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
What role could emerging technologies, such as antimicrobial coatings or biofilm-disrupting agents, play in reducing the incidence of CIED infections?
Related Questions
How do you balance the risk of unnecessary treatment with acyclovir against the risk of delaying treatment in encephalitis cases where CSF pleocytosis is absent?
Do you give chronic antibiotic prophylaxis for recurrent UTIs, including Pseudomonas aeruginosa, in a patient with retained ureteral stents?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
Do you recommend the use of ampicillin/ceftriaxone for prosthetic valve endocarditis due to ampicillin-susceptible Enterococcus faecium?
Do you routinely transition to PO antibiotics for patients with native joint septic arthritis whom have undergone washout and the organism is not s. aureus?
What is your approach in managing patients with suspected super-infected pancreatic pseudocysts that are not yet mature enough for drainage?
Do you recommend, based on current evidence, avoiding antimotility agents in patients with non-fulminant C. difficile infection who have no evidence of ileus?
What duration of therapy do you recommend for patients with a vascular graft infection in which the graft has been removed and another graft placed in the infected space?
Do you routinely use oral vancomycin prophylaxis in patients with a history of CDI who are receiving antibiotics?
What specific criteria or patient conditions would make you hesitant to use fluoroquinolones early in the treatment course for managing MSSA joint infections with oral antibiotics?
